SGLT2 inhibition in cardiology: What is the profile of benefit?
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.
Video navigation menu
- SGLT2 inhibition – mode of action 00:32
- Clinical outcome data on CV benefit of SGLT2 inhibition 01:25
- Potential mechanisms explaining CV effects in SGLT2i outcome trials 03:42
- Disturbed BCAA catabolism in heart failure 07:18
- SGLT2 inhibition and heart failure 08:57
This lecture was part of a CME accredited symposium: "Targeting SGLT2 in clinical cardiology: Exploring the benefits in CV Risk, Diabetes & Heart failure" during ESC 2018 in Munich, Germany.
Prof Nikolaus Marx, MD - Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.